Ascendis Pharma A/S Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities
Ascendis Pharma A/S (ASND) reported Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities of EUR 78.52 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-02-11.
Financial Statements › Cash Flow › Operating Activities
ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities · last filed 2026-02-11
| Period end | Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities 12 month |
|---|---|
| 2025-12-31 | 78.52M EUR 20-F · filed 2026-02-11 |
| 2024-12-31 | 861.00K EUR 20-F · filed 2026-02-11 |
| 2023-12-31 | 2.97M EUR 20-F · filed 2025-02-12 |
| 2022-12-31 | 3.19M EUR 20-F · filed 2024-02-07 |
| 2021-12-31 | 10.81M EUR 20-F · filed 2023-02-16 |